Lin BioScience, Inc.
6696
Clasificación en acciones
#3885
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Precio por acción
$5.06
Capitalización bursátil
$4.20B
Cambio (1 día)
-5.23%
Cambio (1 año)
-44.38%
País
TW
Comercio Lin BioScience, Inc. (6696)
Categoría
Healthcare
Historial del precio de la acción de Lin BioScience, Inc. (6696)
Precio más alto de cierre: $5.41 el 2026-10-01
Precio más bajo de cierre: $1.30 el 2018-10-01
Precio más bajo de cierre: $1.30 el 2018-10-01
Historial del precio de la acción de Lin BioScience, Inc. desde 2018 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -4.14% |
| 2025 | 202.95% |
| 2024 | 13.59% |
| 2023 | -31.65% |
| 2022 | -22.82% |
| 2021 | 101.12% |
| 2020 | 278.57% |
| 2019 | -21.27% |
| 2018 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.79 | -3.81% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
